glp 1 gip glucagon triple agonist Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor Polyagonists Enable Increasingly Effective Treatment
Description
doi: 10.1038/npp.2015.47

Abstract Diabetic Kidney Disease (DKD) is the leading cause of end stage renal disease (ESRD) worldwide

Curr Diab Rep 18(4):20 Bisgaard LS, Bosteen MH, Fink LN, Srensen CM, Rosendahl A, Mogensen CK et al (2016) Liraglutide reduces both atherosclerosis and kidney inflammation in moderately uremic LDLr/ Mice

Podcast: Embed Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | Pandora | iHeartRadio | TuneIn | Deezer | RSS CardioNerds (Drs

Diabetes Care 44, 14331442

Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis
